Letrozolo Mylan Generics

Letrozole, the active ingredient in Letrozolo Mylan Generics, is a aromatase inhibitor presented as a oral tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women. GNH USA supplies Letrozolo Mylan Generics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozole is used in endocrine therapy for hormone‑dependent breast cancer. - Hormone receptor‑positive breast cancer (postmenopausal): reduces estrogen production to slow tumor growth. - Advanced or metastatic breast cancer (postmenopausal): helps control disease progression. - Adjuvant therapy after surgery (postmenopausal): lowers risk of cancer recurrence.

Letrozole may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Hot flashes: transient episodes of increased warmth and sweating. - Joint or muscle pain: mild to moderate arthralgia or myalgia. - Fatigue: general feeling of tiredness. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Severe bone loss: increased risk of osteoporosis and fractures. - Cardiovascular events: rare cases of thrombosis or myocardial infarction. - Liver function abnormalities: elevated transaminases or hepatitis.

Before initiating therapy, clinicians should consider several safety measures. - Monitor bone mineral density: assess risk of osteoporosis and consider supplementation. - Assess cardiovascular risk: evaluate history of thromboembolic disease. - Check liver function: obtain baseline and periodic liver enzyme tests. - Avoid use in premenopausal women: drug is ineffective and may cause harm. - Pregnancy and lactation: contraindicated; discuss alternatives with prescriber. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Letrozole can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent estrogen replacement therapy: may reduce letrozole efficacy. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower plasma concentrations. - Tamoxifen: antagonistic effect on estrogen pathways, diminishing therapeutic benefit.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR; monitor coagulation parameters. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): potential metabolic interaction, observe for side effects. - Diuretics: may exacerbate electrolyte changes; monitor laboratory values.